Lansoprazole
- Generic Name
- Lansoprazole
- Brand Names
- Prevacid, Prevpac
- Drug Type
- Small Molecule
- Chemical Formula
- C16H14F3N3O2S
- CAS Number
- 103577-45-3
- Unique Ingredient Identifier
- 0K5C5T2QPG
- Background
Lansoprazole marketed under the brand Prevacid, is a proton pump inhibitor (PPI) and is structurally classified as a substituted benzimidazole. It reduces gastric acid secretion by targeting gastric H,K-ATPase pumps and is thus effective at promoting healing in ulcerative diseases, and treating gastroesophageal reflux disease (GERD) along with other patholog...
- Indication
Lansoprazole is used to reduce gastric acid secretion and is approved for short term treatment of active gastric ulcers, active duodenal ulcers, erosive reflux oesophagitis, symptomatic gastroesophageal reflux disease, and non-steroidal anti-inflammatory drug (NSAID) induced gastric and duodenal ulcers. It may be used in the maintenance and healing of sever...
- Associated Conditions
- Duodenal Ulcer, Erosive Esophagitis, Helicobacter Pylori Infection, Symptomatic Gastroesophageal Reflux Disease (sGERD), Ulcer Healing, Zollinger-Ellison Syndrome, Active Duodenal ulcer, Develop NSAID-induced gastric ulcers, Hypersecretory conditions, Maintenance of healing Erosive esophagitis
- Associated Therapies
- -
Lansoprazole Preventing Gastroduodenal Stress Ulcerations
- Conditions
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2008-01-11
- Lead Sponsor
- Temple University
- Target Recruit Count
- 40
- Registration Number
- NCT00220909
- Locations
- 🇺🇸
Temple University School of Medicine, Philadelphia, Pennsylvania, United States
Proton Pump Inhibitor Therapy for Mild to Moderate Obstructive Sleep Apnea
- Conditions
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2018-12-10
- Lead Sponsor
- MetroHealth Medical Center
- Registration Number
- NCT00211614
- Locations
- 🇺🇸
MetroHealth Medical Center, Cleveland, Ohio, United States
Intravenous vs Oral Lansoprazole on Gastric Acid Secretion in Subjects With Erosive Esophagitis
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2010-07-21
- Lead Sponsor
- Takeda
- Target Recruit Count
- 68
- Registration Number
- NCT00175045
A Study to Evaluate the Effect of Lansoprazole on Hospitalized Neonates With Gastroesophageal Reflux Disease
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2010-07-22
- Lead Sponsor
- Takeda
- Target Recruit Count
- 24
- Registration Number
- NCT00174928
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.